[go: up one dir, main page]

EP1261380A1 - Acides nucleiques, proteines et anticorps - Google Patents

Acides nucleiques, proteines et anticorps

Info

Publication number
EP1261380A1
EP1261380A1 EP01912649A EP01912649A EP1261380A1 EP 1261380 A1 EP1261380 A1 EP 1261380A1 EP 01912649 A EP01912649 A EP 01912649A EP 01912649 A EP01912649 A EP 01912649A EP 1261380 A1 EP1261380 A1 EP 1261380A1
Authority
EP
European Patent Office
Prior art keywords
polypeptide
seq
sequence
polypeptides
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01912649A
Other languages
German (de)
English (en)
Inventor
Craig A. Rosen
Steven C. Barash
Steven M. Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority claimed from PCT/US2001/001312 external-priority patent/WO2001054733A1/fr
Publication of EP1261380A1 publication Critical patent/EP1261380A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • RPTKs receptor protein tyrosine kinases
  • EGF epidermal growth factor
  • EGFR epidermal growth factor receptor
  • cyclin dependent kinase 2 (cdk2), a kinase important in regulating cellular proliferation
  • cdk2 cyclin dependent kinase 2
  • NEGFR vascular endothelial growth factor receptor
  • Inhibition of VEGFR activity reduces or eliminates the vascularization of tumors directed by NEGFR.
  • An antagonistic monoclonal antibody, herceptin, against the erbB2 receptor tyrosine kinase is being used in breast cancer therapies to treat breast cancers where ErbB2 is overexpressed.
  • the fourth column provides a unique integer 'a' where 'a' is any integer between 1 and the final nucleotide minus 15 of SEQ ID NO:X
  • the fifth column provides a unique integer 'b' where 'b' is any integer between 15 and the final nucleotide of SEQ ID NO:X, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where b is greater than or equal to a + 14.
  • the uniquely defined integers can be substituted into the general formula of a-b, and used to describe polynucleotides which may be preferably excluded from the invention.
  • preferably excluded from the invention are at least one, two, three, four, five, ten, or more of the polynucleotide sequence(s) having the accession number(s) disclosed in the sixth column of this Table (including for example, published sequence in connection with a particular BAC clone).
  • preferably excluded from the invention are the specific polynucleotide sequence(s) contained in the clones corresponding to at least one, two, three, four, five, ten, or more of the available material having the accession numbers identified in the sixth column of this Table (including for example, the actual sequence contained in an identified BAC clone).
  • the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).
  • HCE3W04 379 615501 AC022366 1466 1-565 1503-1718 1838-1933 2011-2097 2265-2335 2588-2693 2905-2975 3090-3726 3809-3889 4080-4591 4847-5070 5355-5819
  • the fourth column provides a BAC identifier "BAC ID NO: A” for the BAC clone referenced in the corresponding row of the table.
  • the fifth column provides the nucleotide sequence identifier, "SEQ ID NO:B" for a fragment of the BAC clone identified in column four of the corresponding row of the table.
  • the sixth column provides the location (i.e., nucleotide position numbers) within the polynucleotide sequence of SEQ ID NO:B which delineate certain polynucleotides of the invention that are also exemplary members of polynucleotide sequences that encode polypeptides of the invention (e.g., polypeptides containing amino acid sequences encoded by the polynucleotide sequences delineated in column six, and fragments and variants thereof).
  • polypeptides of the invention can be prepared in any suitable manner.
  • Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.
  • polynucleotides of the invention comprise, or alternatively consist of, one, two, three, four, five, six, seven, eight, nine, ten, or more of the complementary strand(s) of the sequences delineated in column 6 of Table IB which correspond to the same Clone ID NO:Z (see Table IB, column 1), or any combination thereof.
  • the above-described polynucleotides of the invention comprise, or alternatively consist of, sequences delineated in column 6 of Table IB which correspond to the same Clone ID NO:Z (see Table IB, column 1) and have a nucleic acid sequence which is different from that of the BAC fragment having the sequence disclosed in SEQ ID NO:B (see Table IB, column 5).
  • polynucleotides of the invention comprise, or alternatively consist of a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table IB and the 5' 10 polynucleotides of the sequence of SEQ ID NO:X are directly contiguous.
  • polynucleotides of the invention -comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of the sequence of SEQ ID NO:X and the 5' 10 polynucleotides of the sequence of one of the sequences delineated in column 6 of Table IB are directly contiguous. Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions, are also encompassed by the invention.
  • Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the mvention.
  • polynucleotides of the invention comprise, or alternatively consist of, a polynucleotide sequence in which the 3' 10 polynucleotides of one of the sequences delineated in column 6 of Table IB and the 5' 10 polynucleotides of another sequence in column 6 corresponding to the same Clone ID NO:Z (see Table IB, column 1) are directly contiguous. Nucleic acids which hybridize to the complement of these 20 lower stringency conditions, are also encompassed by the invention.
  • Nucleic acids which hybridize to the complement of these 20 contiguous polynucleotides under stringent hybridization conditions or alternatively, under lower stringency conditions are also encompassed by the mvention.
  • Polypeptides encoded by these polynucleotides and/or nucleic acids, other polynucleotides and/or nucleic acids encoding these polypeptides, and antibodies that bind these polypeptides are also encompassed by the invention. Additionally, fragments and variants of the above-described polynucleotides, nucleic acids, and polypeptides are also encompassed by the invention.
  • polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a and b are integers as defined in columns 4 and 5, respectively, of Table 3.
  • the polynucleotides of the invention do not consist of at least one, two, three, four, five, ten, or more of the specific polynucleotide sequences referenced by the Genbank Accession No. as disclosed in column 6 of Table 3 (including for example, published sequence in connection with a particular BAC clone).
  • HUTSF11 241 966029 1 - 416 15 - 430 AI384010, AI288640, Z20435, and A74523.
  • polypeptide and Polypeptide Variants [98] The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X or the complementary strand thereto, nucleotide sequences encoding the polypeptide of SEQ ID NO:Y, the nucleotide sequence of SEQ ID NO:X encoding the polypeptide sequence as defined in column 7 of Table 1A, nucleotide sequences encoding the polypeptide as defined in column 7 of Table 1 A, the nucleotide sequence as defined in columns 8 and 9 of Table 2, nucleotide sequences encoding the polypeptide encoded by the nucleotide sequence as defined in columns 8 and 9 of Table 2, the nucleotide sequence as defined in column 6 of Table IB, nucleotide sequences encoding the polypeptide encoded by the nucleotide sequence as defined in column 6 of Table IB, the cDNA sequence contained in Clone ID NO:Z, and/or nucleotide sequences
  • one aspect of the invention provides an isolated nucleic acid molecule comprising, or alternatively consisting of, a polynucleotide having a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence described in SEQ ID NO:X or contained in the cDNA sequence of Clone ID NO:Z; (b) a nucleotide sequence in SEQ ID NO:X or the cDNA in Clone ID NO:Z which encodes the complete amino acid sequence of SEQ ID NO:Y or the complete amino acid sequence encoded by the cDNA in Clone ID NO:Z; (c) a nucleotide sequence in SEQ ID NO:X or the cDNA in Clone ID NO:Z which encodes a mature polypeptide; (d) a nucleotide sequence in SEQ ID NO:X or the cDNA sequence of Clone ID NO:Z, which encodes a biologically active fragment of a polypeptide; (e) a nucleotide sequence
  • the present mvention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%> or 100%), identical to, for example, any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), (i), or (j) above, the nucleotide coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence of the cDNA contained in Clone ID NO:Z or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding a polypeptide sequence encoded by the nucleotide sequence in SEQ ID NO:X, a polypeptide sequence encoded by the complement of the polynucleotide sequence in SEQ ID NO:X,
  • polynucleotides which hybridize to the complement of these nucleic acid molecules under stringent hybridization conditions or alternatively, under lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides and nucleic acids.
  • the invention encompasses nucleic acid molecules which comprise, or alternatively, consist of a polynucleotide which hybridizes under stringent hybridization conditions, or alternatively, under lower stringency conditions, to a polynucleotide in (a), (b), (c), (d), (e), (f), (g), (h), or (i), above, as are polypeptides encoded by these polynucleotides.
  • the percent identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment.
  • a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity.
  • the deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end.
  • the 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly matched the final percent identity would be 90%.
  • a 90 base subject sequence is compared with a 100 base query sequence.
  • deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query.
  • percent identity calculated by FASTDB is not manually corrected.
  • bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte: sur de nouvelles protéines: plus spécifiquement sur des molécules isolées d'acide nucléique codant pour de nouveaux polypeptides; sur de nouveaux polypeptides et anticorps se fixant à ces polypeptides; sur des vecteurs, des cellules hôtes, et des méthodes de recombinaison et de synthèse, servant à produire des polynucléotides et/ou polypeptides et anticorps humains; sur des méthodes diagnostiques et thérapeutiques permettant de diagnostiquer, traiter, prévenir et/ou pronostiquer des troubles liés à ces nouveaux polypeptides; sur des procédés de criblage permettant d'identifier les agonistes et antagonistes des polynucléotides et polypeptides de l'invention; et sur des procédés et/ou préparations inhibant ou accroissant la production et le fonctionnement des polypeptides de l'invention.
EP01912649A 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps Withdrawn EP1261380A1 (fr)

Applications Claiming Priority (235)

Application Number Priority Date Filing Date Title
US17906500P 2000-01-31 2000-01-31
US179065P 2000-01-31
US18062800P 2000-02-04 2000-02-04
US180628P 2000-02-04
US18466400P 2000-02-24 2000-02-24
US184664P 2000-02-24
US18635000P 2000-03-02 2000-03-02
US186350P 2000-03-02
US18987400P 2000-03-16 2000-03-16
US189874P 2000-03-16
US19007600P 2000-03-17 2000-03-17
US190076P 2000-03-17
US19812300P 2000-04-18 2000-04-18
US198123P 2000-04-18
US20551500P 2000-05-19 2000-05-19
US205515P 2000-05-19
US20946700P 2000-06-07 2000-06-07
US209467P 2000-06-07
US21488600P 2000-06-28 2000-06-28
US214886P 2000-06-28
US21513500P 2000-06-30 2000-06-30
US215135P 2000-06-30
US21688000P 2000-07-07 2000-07-07
US21664700P 2000-07-07 2000-07-07
US216880P 2000-07-07
US216647P 2000-07-07
US21749600P 2000-07-11 2000-07-11
US21748700P 2000-07-11 2000-07-11
US217496P 2000-07-11
US217487P 2000-07-11
US21829000P 2000-07-14 2000-07-14
US218290P 2000-07-14
US22096300P 2000-07-26 2000-07-26
US22096400P 2000-07-26 2000-07-26
US220963P 2000-07-26
US220964P 2000-07-26
US22526700P 2000-08-14 2000-08-14
US22575900P 2000-08-14 2000-08-14
US22527000P 2000-08-14 2000-08-14
US22526800P 2000-08-14 2000-08-14
US22451800P 2000-08-14 2000-08-14
US22544700P 2000-08-14 2000-08-14
US22575700P 2000-08-14 2000-08-14
US22526600P 2000-08-14 2000-08-14
US22521400P 2000-08-14 2000-08-14
US22521300P 2000-08-14 2000-08-14
US22575800P 2000-08-14 2000-08-14
US22451900P 2000-08-14 2000-08-14
US225270P 2000-08-14
US225268P 2000-08-14
US225447P 2000-08-14
US225757P 2000-08-14
US225214P 2000-08-14
US225266P 2000-08-14
US225267P 2000-08-14
US225213P 2000-08-14
US224518P 2000-08-14
US225759P 2000-08-14
US224519P 2000-08-14
US225758P 2000-08-14
US22627900P 2000-08-18 2000-08-18
US226279P 2000-08-18
US22686800P 2000-08-22 2000-08-22
US22718200P 2000-08-22 2000-08-22
US22668100P 2000-08-22 2000-08-22
US227182P 2000-08-22
US226868P 2000-08-22
US226681P 2000-08-22
US22700900P 2000-08-23 2000-08-23
US227009P 2000-08-23
US22892400P 2000-08-30 2000-08-30
US228924P 2000-08-30
US22934500P 2000-09-01 2000-09-01
US22934400P 2000-09-01 2000-09-01
US22928700P 2000-09-01 2000-09-01
US22934300P 2000-09-01 2000-09-01
US229344P 2000-09-01
US229287P 2000-09-01
US229345P 2000-09-01
US229343P 2000-09-01
US22951300P 2000-09-05 2000-09-05
US22950900P 2000-09-05 2000-09-05
US229513P 2000-09-05
US229509P 2000-09-05
US23043700P 2000-09-06 2000-09-06
US23043800P 2000-09-06 2000-09-06
US230438P 2000-09-06
US230437P 2000-09-06
US23141400P 2000-09-08 2000-09-08
US23124200P 2000-09-08 2000-09-08
US23208000P 2000-09-08 2000-09-08
US23141300P 2000-09-08 2000-09-08
US23208100P 2000-09-08 2000-09-08
US23124300P 2000-09-08 2000-09-08
US23124400P 2000-09-08 2000-09-08
US232081P 2000-09-08
US231244P 2000-09-08
US231413P 2000-09-08
US231242P 2000-09-08
US231414P 2000-09-08
US231243P 2000-09-08
US232080P 2000-09-08
US23196800P 2000-09-12 2000-09-12
US231968P 2000-09-12
US23306400P 2000-09-14 2000-09-14
US23239700P 2000-09-14 2000-09-14
US23306300P 2000-09-14 2000-09-14
US23240100P 2000-09-14 2000-09-14
US23239900P 2000-09-14 2000-09-14
US23240000P 2000-09-14 2000-09-14
US23306500P 2000-09-14 2000-09-14
US23239800P 2000-09-14 2000-09-14
US232401P 2000-09-14
US233065P 2000-09-14
US232398P 2000-09-14
US233063P 2000-09-14
US232400P 2000-09-14
US232399P 2000-09-14
US233064P 2000-09-14
US232397P 2000-09-14
US23422300P 2000-09-21 2000-09-21
US234274P 2000-09-21
US234223P 2000-09-21
US234998P 2000-09-25
US234997P 2000-09-25
US235484P 2000-09-26
US235836P 2000-09-27
US235834P 2000-09-27
US236369P 2000-09-29
US236367P 2000-09-29
US236327P 2000-09-29
US236370P 2000-09-29
US236368P 2000-09-29
US237038P 2000-10-02
US237039P 2000-10-02
US237037P 2000-10-02
US236802P 2000-10-02
US237040P 2000-10-02
US239937P 2000-10-13
US239935P 2000-10-13
US241808P 2000-10-20
US241785P 2000-10-20
US241786P 2000-10-20
US241221P 2000-10-20
US241787P 2000-10-20
US240960P 2000-10-20
US241826P 2000-10-20
US241809P 2000-10-20
US244617P 2000-11-01
US24660900P 2000-11-08 2000-11-08
US24661300P 2000-11-08 2000-11-08
US24652300P 2000-11-08 2000-11-08
US24652400P 2000-11-08 2000-11-08
US24647800P 2000-11-08 2000-11-08
US246610P 2000-11-08
US246532P 2000-11-08
US246609P 2000-11-08
US246523P 2000-11-08
US246524P 2000-11-08
US246525P 2000-11-08
US246527P 2000-11-08
US246613P 2000-11-08
US246526P 2000-11-08
US246474P 2000-11-08
US246477P 2000-11-08
US246476P 2000-11-08
US246528P 2000-11-08
US246475P 2000-11-08
US246611P 2000-11-08
US246478P 2000-11-08
US24926400P 2000-11-17 2000-11-17
US24924400P 2000-11-17 2000-11-17
US24930000P 2000-11-17 2000-11-17
US24921600P 2000-11-17 2000-11-17
US24920700P 2000-11-17 2000-11-17
US24929700P 2000-11-17 2000-11-17
US24921800P 2000-11-17 2000-11-17
US24920900P 2000-11-17 2000-11-17
US24920800P 2000-11-17 2000-11-17
US24921100P 2000-11-17 2000-11-17
US24921200P 2000-11-17 2000-11-17
US24921300P 2000-11-17 2000-11-17
US24921000P 2000-11-17 2000-11-17
US24924500P 2000-11-17 2000-11-17
US24929900P 2000-11-17 2000-11-17
US24921400P 2000-11-17 2000-11-17
US24921700P 2000-11-17 2000-11-17
US24921500P 2000-11-17 2000-11-17
US24926500P 2000-11-17 2000-11-17
US249213P 2000-11-17
US249207P 2000-11-17
US249212P 2000-11-17
US249217P 2000-11-17
US249210P 2000-11-17
US249215P 2000-11-17
US249264P 2000-11-17
US249300P 2000-11-17
US249244P 2000-11-17
US249214P 2000-11-17
US249297P 2000-11-17
US249265P 2000-11-17
US249209P 2000-11-17
US249216P 2000-11-17
US249245P 2000-11-17
US249218P 2000-11-17
US249299P 2000-11-17
US249208P 2000-11-17
US249211P 2000-11-17
US25039100P 2000-12-01 2000-12-01
US25016000P 2000-12-01 2000-12-01
US250160P 2000-12-01
US250391P 2000-12-01
US25103000P 2000-12-05 2000-12-05
US25198800P 2000-12-05 2000-12-05
US25671900P 2000-12-05 2000-12-05
US256719P 2000-12-05
US251988P 2000-12-05
US251030P 2000-12-05
US25147900P 2000-12-06 2000-12-06
US251479P 2000-12-06
US25198900P 2000-12-08 2000-12-08
US25185600P 2000-12-08 2000-12-08
US25186800P 2000-12-08 2000-12-08
US25186900P 2000-12-08 2000-12-08
US25199000P 2000-12-08 2000-12-08
US251856P 2000-12-08
US251989P 2000-12-08
US251868P 2000-12-08
US251990P 2000-12-08
US251869P 2000-12-08
US25409700P 2000-12-11 2000-12-11
US254097P 2000-12-11
US25967801P 2001-01-05 2001-01-05
US259678P 2001-01-05
PCT/US2001/001312 WO2001054733A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Publications (1)

Publication Number Publication Date
EP1261380A1 true EP1261380A1 (fr) 2002-12-04

Family

ID=27587097

Family Applications (38)

Application Number Title Priority Date Filing Date
EP01912655A Withdrawn EP1261703A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et antigenes
EP01908611A Withdrawn EP1261633A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912654A Withdrawn EP1254172A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01914331A Withdrawn EP1254173A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912658A Withdrawn EP1254248A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910330A Withdrawn EP1255768A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
EP01908617A Withdrawn EP1252290A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910331A Withdrawn EP1259540A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01920103A Withdrawn EP1261637A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910326A Withdrawn EP1252289A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912653A Withdrawn EP1252185A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01918156A Withdrawn EP1254151A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
EP01910334A Withdrawn EP1259642A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01924081A Withdrawn EP1254153A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01922230A Withdrawn EP1259526A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01924085A Withdrawn EP1261745A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912651A Withdrawn EP1252303A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910337A Withdrawn EP1255776A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910332A Withdrawn EP1255864A1 (fr) 2000-01-31 2001-01-17 Acides nucl iques, proteines et anticorps
EP01912650A Withdrawn EP1255777A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912657A Withdrawn EP1261618A2 (fr) 2000-01-31 2001-01-17 Acides ncleiques, proteines et anticorps
EP01924086A Withdrawn EP1259531A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01914330A Withdrawn EP1252297A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910336A Withdrawn EP1252302A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01926335A Withdrawn EP1263944A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01916068A Withdrawn EP1255817A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910328A Withdrawn EP1261634A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912656A Withdrawn EP1252176A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01920102A Withdrawn EP1254152A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
EP01910329A Withdrawn EP1255766A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910335A Withdrawn EP1254218A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01924084A Withdrawn EP1265910A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912652A Withdrawn EP1254171A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910325A Withdrawn EP1254219A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01928288A Withdrawn EP1254147A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912649A Withdrawn EP1261380A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912662A Withdrawn EP1255767A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912664A Withdrawn EP1255778A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Family Applications Before (35)

Application Number Title Priority Date Filing Date
EP01912655A Withdrawn EP1261703A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et antigenes
EP01908611A Withdrawn EP1261633A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912654A Withdrawn EP1254172A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01914331A Withdrawn EP1254173A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912658A Withdrawn EP1254248A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910330A Withdrawn EP1255768A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
EP01908617A Withdrawn EP1252290A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910331A Withdrawn EP1259540A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01920103A Withdrawn EP1261637A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910326A Withdrawn EP1252289A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912653A Withdrawn EP1252185A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01918156A Withdrawn EP1254151A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
EP01910334A Withdrawn EP1259642A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01924081A Withdrawn EP1254153A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01922230A Withdrawn EP1259526A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01924085A Withdrawn EP1261745A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912651A Withdrawn EP1252303A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910337A Withdrawn EP1255776A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910332A Withdrawn EP1255864A1 (fr) 2000-01-31 2001-01-17 Acides nucl iques, proteines et anticorps
EP01912650A Withdrawn EP1255777A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912657A Withdrawn EP1261618A2 (fr) 2000-01-31 2001-01-17 Acides ncleiques, proteines et anticorps
EP01924086A Withdrawn EP1259531A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01914330A Withdrawn EP1252297A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910336A Withdrawn EP1252302A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01926335A Withdrawn EP1263944A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01916068A Withdrawn EP1255817A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910328A Withdrawn EP1261634A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912656A Withdrawn EP1252176A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01920102A Withdrawn EP1254152A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines, et anticorps
EP01910329A Withdrawn EP1255766A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910335A Withdrawn EP1254218A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01924084A Withdrawn EP1265910A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912652A Withdrawn EP1254171A1 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01910325A Withdrawn EP1254219A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01928288A Withdrawn EP1254147A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP01912662A Withdrawn EP1255767A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
EP01912664A Withdrawn EP1255778A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Country Status (1)

Country Link
EP (38) EP1261703A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
RU2678127C2 (ru) 2012-11-13 2019-01-23 Бионтех Аг Агенты для лечения экспрессирующих клаудин раковых заболеваний
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0154733A1 *

Also Published As

Publication number Publication date
EP1265910A2 (fr) 2002-12-18
EP1261637A1 (fr) 2002-12-04
EP1254219A2 (fr) 2002-11-06
EP1261703A1 (fr) 2002-12-04
EP1255767A2 (fr) 2002-11-13
EP1252290A1 (fr) 2002-10-30
EP1255864A1 (fr) 2002-11-13
EP1254152A2 (fr) 2002-11-06
EP1254171A1 (fr) 2002-11-06
EP1252302A2 (fr) 2002-10-30
EP1252303A2 (fr) 2002-10-30
EP1254151A1 (fr) 2002-11-06
EP1261618A2 (fr) 2002-12-04
EP1252176A2 (fr) 2002-10-30
EP1259526A2 (fr) 2002-11-27
EP1263944A2 (fr) 2002-12-11
EP1252289A2 (fr) 2002-10-30
EP1254147A2 (fr) 2002-11-06
EP1254248A2 (fr) 2002-11-06
EP1259642A1 (fr) 2002-11-27
EP1261634A1 (fr) 2002-12-04
EP1254172A1 (fr) 2002-11-06
EP1261633A2 (fr) 2002-12-04
EP1255768A2 (fr) 2002-11-13
EP1255817A1 (fr) 2002-11-13
EP1252185A1 (fr) 2002-10-30
EP1254153A2 (fr) 2002-11-06
EP1254218A2 (fr) 2002-11-06
EP1255766A2 (fr) 2002-11-13
EP1255776A1 (fr) 2002-11-13
EP1259531A2 (fr) 2002-11-27
EP1255778A2 (fr) 2002-11-13
EP1259540A1 (fr) 2002-11-27
EP1255777A1 (fr) 2002-11-13
EP1252297A1 (fr) 2002-10-30
EP1254173A1 (fr) 2002-11-06
EP1261745A2 (fr) 2002-12-04

Similar Documents

Publication Publication Date Title
WO2001054733A1 (fr) Acides nucleiques, proteines et anticorps
WO2001055306A2 (fr) Acides nucleiques, proteines, et anticorps
WO2001055326A2 (fr) Acides nucleiques, proteines et anticorps
WO2002026930A2 (fr) Acides nucleiques, proteines et anticorps
WO2001055164A1 (fr) Acides nucleiques, proteines et anticorps
EP1261380A1 (fr) Acides nucleiques, proteines et anticorps
WO2001055388A1 (fr) Acides nucleiques, proteines et anticorps
WO2001055167A1 (fr) Acides nucleiques, proteines et anticorps
WO2003072761A1 (fr) 20 proteines humaines secretees
WO2001055162A1 (fr) Acides nucleiques, proteines et anticorps
EP1268527A2 (fr) Acides nucleiques, proteines et anticorps
EP1254228A1 (fr) Acides nucleiques, proteines et anticorps
EP1254217A2 (fr) Acides nucl iques, prot ines et anticorps
WO2001055329A2 (fr) Acides nucleiques, proteines et anticorps
EP1254170A2 (fr) Acides nucleiques, proteines et anticorps
WO2001055305A2 (fr) Acides nucleiques, proteines, et anticorps
EP1259528A1 (fr) Acides nucleiques, proteines, et anticorps

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020829

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20021126